These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16613570)

  • 1. Nitric oxide and inflammation.
    Cirino G; Distrutti E; Wallace JL
    Inflamm Allergy Drug Targets; 2006 Apr; 5(2):115-9. PubMed ID: 16613570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric-sparing nitric oxide-releasable 'true' prodrugs of aspirin and naproxen.
    Gund M; Gaikwad P; Borhade N; Burhan A; Desai DC; Sharma A; Dhiman M; Patil M; Sheikh J; Thakre G; Tipparam SG; Sharma S; Nemmani KVS; Satyam A
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5587-5592. PubMed ID: 25466180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NO-NSAIDs and cancer: promising novel agents.
    Rigas B; Kalofonos H; Lebovics E; Vagenakis AG
    Dig Liver Dis; 2003 May; 35 Suppl 2():S27-34. PubMed ID: 12846441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
    Chattopadhyay M; Goswami S; Rodes DB; Kodela R; Velazquez CA; Boring D; Crowell JA; Kashfi K
    Cancer Lett; 2010 Dec; 298(2):204-11. PubMed ID: 20674154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide-modulating agents for gastrointestinal disorders.
    Whittle BJ
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1347-58. PubMed ID: 16255675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NO-NSAIDs: from inflammatory mediators to clinical readouts.
    Fiorucci S; Antonelli E
    Inflamm Allergy Drug Targets; 2006 Apr; 5(2):121-31. PubMed ID: 16613571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen.
    Drugs R D; 2006; 7(4):262-6. PubMed ID: 16784252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs].
    Zhang YH; Ji H; Peng SX
    Yao Xue Xue Bao; 2007 Apr; 42(4):352-7. PubMed ID: 17633199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
    Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen.
    Amoruso A; Fresu LG; Dalli J; Miglietta D; Bardelli C; Federici Canova D; Perretti M; Brunelleschi S
    Life Sci; 2015 Apr; 126():28-36. PubMed ID: 25711428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha.
    Fiorucci S; Santucci L; Federici B; Antonelli E; Distrutti E; Morelli O; Renzo GD; Coata G; Cirino G; Soldato PD; Morelli A
    Aliment Pharmacol Ther; 1999 Mar; 13(3):421-35. PubMed ID: 10102977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCX-701. NicOx.
    Joshi GP
    Curr Opin Investig Drugs; 2004 Jul; 5(7):755-9. PubMed ID: 15298073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NO-naproxen (AstraZeneca).
    Monck N
    IDrugs; 2003 Jun; 6(6):593-9. PubMed ID: 12811683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor.
    Pini A; Viappiani S; Bolla M; Masini E; Bani D
    J Pharmacol Exp Ther; 2012 May; 341(2):493-9. PubMed ID: 22344408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection.
    Wallace JL
    Inflamm Allergy Drug Targets; 2006 Apr; 5(2):133-7. PubMed ID: 16613572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease.
    Wallace JL
    Dig Liver Dis; 2003 May; 35 Suppl 2():S35-40. PubMed ID: 12846442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
    Fiorucci S; Santucci L; Distrutti E
    Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide-releasing NSAIDs: a review of their current status.
    Fiorucci S; Antonelli E; Burgaud JL; Morelli A
    Drug Saf; 2001; 24(11):801-11. PubMed ID: 11665868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs.
    Aisa MC; Datti A; Orlacchio A; Di Renzo GC
    Life Sci; 2018 Sep; 208():10-19. PubMed ID: 29990484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripherally acting analgesics.
    Amadio P
    Am J Med; 1984 Sep; 77(3A):17-26. PubMed ID: 6486127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.